Immuno-Oncology News Articles | Page 2

Immunotherapy/RT Combos Could Be Next Wave of Novel Treatment in Lung Cancers
Sagus Sampath, MD, discusses ongoing studies exploring checkpoint inhibitors with radiation therapy and the promise of integrating these 2 treatments in the field of non-small cell lung cancer.
Future of Immunotherapy in Ovarian Cancer to Include Combinations
Bradley J. Monk, MD, discusses pivotal trials, as well as the potential for immunotherapy in ovarian cancer.
FDA Grants Frontline Avelumab/Axitinib Breakthrough Designation for RCC
The FDA has granted the PD-L1 inhibitor avelumab a breakthrough therapy designation for use in combination with the VEGF inhibitor axitinib in treatment-naïve patients with advanced renal cell carcinoma.
 
Future of Bladder Cancer Likely to Be Combination Immunotherapy
Arjun Balar, MD, discusses novel immunotherapy combinations for the treatment of patients with bladder cancer.
Immunotherapy and EGFR, ALK Inhibitors Deliver Precision Medicine in NSCLC
Edward S. Kim, MD, discusses the advancements in lung cancer in 2017, specifically in EGFR- and ALK-positive patients and those with PD-L1 expression.
FDA Approves Adjuvant Nivolumab for Melanoma
The FDA has approved nivolumab as an adjuvant treatment for patients with completely resected melanoma with lymph node involvement or metastatic disease.
Frontline Findings Put Fresh Focus on Immunotherapy in NSCLC
Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non
Pembrolizumab Investigated as Adjuvant RCC Therapy
Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.
Immunotherapy Resistance Remains a Puzzle
Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.
Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.
Publication Bottom Border
Border Publication
x